Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 3/20 | 0.35 |
| ▸ | HTR1A | P08908 | 2/20 | 0.35 |
| ▸ | DRD2 | P14416 | 2/20 | 0.35 |
| ▸ | HTR6 | P50406 | 2/20 | 0.35 |
| ▸ | ESR1 | P03372 | 9/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.34 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | CCR3 | P51677 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | HRH2 | P25021 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27152115 | 1.00 | HTR7 (0.35) | HTR7HTR1ADRD2HTR6ESR1 | |
| SCHEMBL23100714 | 0.90 | ESR1 (0.40) | ESR1KCNH2CYP3A4 | |
| SCHEMBL24913045 | 0.84 | POLB (0.33) | ESR1KCNH2CCR3 | |
| SCHEMBL30346693 | 0.82 | KDM4E (0.44) | HTR7HTR1ADRD2HTR6ESR1 | |
| SCHEMBL27421096 | 0.81 | PABPC1 (0.44) | ESR1KCNH2PABPC1KDM4ECYP3A4 | |
| SCHEMBL26084330 | 0.79 | STS (0.39) | ESR1KCNH2PABPC1CYP3A4 | |
| SCHEMBL23127014 | 0.77 | ESR1 (0.39) | ESR1KCNH2CYP3A4 | |
| SCHEMBL24162533 | 0.77 | CARM1 (0.37) | ESR1KCNH2CYP3A4 | |
| SCHEMBL27105191 | 0.77 | CARM1 (0.37) | HTR7DRD2HTR6ESR1CCR3 | |
| SCHEMBL23127017 | 0.76 | ESR1 (0.37) | ESR1KCNH2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4577534-A1 | NOVEL SUBSTITUTED TETRAHYDROISOQUINOLINE-6- CARBOXYLIC ACID DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | Sanofi (FR) | 2025-07-02 | — | — | EP | disclosed |
| CN-119907798-A | Novel substituted 2,3,4, 9-tetrahydro-1H-pyrido [3,4-B ] indolecarboxylic acid derivatives, process for their preparation and their therapeutic use | 赛诺菲 | 2025-04-29 | — | — | CN | disclosed |
| CN-119790048-A | Novel substituted tetrahydroisoquinoline-6-carboxylic acid derivatives, process for their preparation and their therapeutic use | 赛诺菲 | 2025-04-08 | — | — | CN | disclosed |
| US-20240208932-A1 | ARYLAMINO DERIVATIVE ESTROGEN RECEPTOR MODULATOR AND USE THEREOF | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2024-06-27 | — | — | US | disclosed |
| US-20240208932-A1 | ARYLAMINO DERIVATIVE ESTROGEN RECEPTOR MODULATOR AND USE THEREOF | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2024-06-27 | — | — | US | disclosed |
| US-20240208932-A1 | ARYLAMINO DERIVATIVE ESTROGEN RECEPTOR MODULATOR AND USE THEREOF | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2024-06-27 | — | — | US | disclosed |
| EP-4371977-A1 | ARYLAMINO DERIVATIVE ESTROGEN RECEPTOR MODULATOR AND USE THEREOF | Xizang Haisco Pharmaceutical Co., Ltd. (CN) | 2024-05-22 | — | — | EP | disclosed |
| WO-2024042185-A1 | NOVEL SUBSTITUTED TETRAHYDROISOQUINOLINE-6- CARBOXYLIC ACID DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF. | SANOFI (FR) | 2024-02-29 | — | — | WO | disclosed |
| WO-2024042163-A1 | NOVEL SUBSTITUTED 2,3,4,9-TETRAHYDRO-1H-PYRIDO[3,4-B]INDOLE CARBOXYLIC ACID DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | SANOFI (FR) | 2024-02-29 | — | — | WO | disclosed |
| WO-2023284837-A1 | ARYLAMINO DERIVATIVE ESTROGEN RECEPTOR MODULATOR AND USE THEREOF | 四川海思科制药有限公司 | 2023-01-19 | — | — | WO | disclosed |
| CN-115611895-A | Arylamino derivative estrogen receptor modulators and uses thereof | 四川海思科制药有限公司 | 2023-01-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208932-A1 | ARYLAMINO DERIVATIVE ESTROGEN RECEPTOR MODULATOR AND USE THEREOF | GPER1, ESR1, ESRRA | HTR7 282/4885HTR1A 304/4885DRD2 674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.